Home » Stocks » NBIX

Neurocrine Biosciences, Inc. (NBIX)

Stock Price: $98.77 USD 1.60 (1.65%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 9.23B
Revenue (ttm) 1.04B
Net Income (ttm) 93.40M
Shares Out 93.30M
EPS (ttm) 0.96
PE Ratio 102.89
Forward PE 24.33
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $98.77
Previous Close $97.17
Change ($) 1.60
Change (%) 1.65%
Day's Open 97.40
Day's Range 96.91 - 100.00
Day's Volume 865,484
52-Week Range 75.11 - 135.15

More Stats

Market Cap 9.23B
Enterprise Value 8.79B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 93.30M
Float n/a
EPS (basic) 1.01
EPS (diluted) 0.96
FCF / Share 2.50
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.97%
FCF Yield 2.52%
Payout Ratio n/a
Shares Short 4.83M
Short Ratio 5.15
Short % of Float n/a
Beta 1.14
PE Ratio 102.89
Forward PE 24.33
P/FCF Ratio 39.62
PS Ratio 8.86
PB Ratio 11.10
Revenue 1.04B
Operating Income 139.92M
Net Income 93.40M
Free Cash Flow 232.94M
Net Cash 439.90M
Net Cash / Share 4.71
Gross Margin 55.72%
Operating Margin 13.43%
Profit Margin 9.00%
FCF Margin 22.35%
ROA 15.87%
ROE 13.55%
ROIC 11.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (25)

Buy 15
Overweight 1
Hold 9
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$125.75*
(27.32% upside)
Low
90.0
Current: $98.77
High
161.0
Target: 125.75
*Average 12-month price target from 22 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue78845116215.0019.77-2.9253.1477.4133.50
Revenue Growth74.65%179.19%977.51%-24.12%---94.51%-31.36%131.08%-
Gross Profit78144616015.0019.77-2.9253.1477.4133.50
Operating Income72.2836.90-131-147-94.20-64.41-49.681.4533.92-13.72
Net Income37.0121.11-143-141-88.93-60.54-46.095.0337.57-7.97
Shares Outstanding91.6390.2488.0986.7184.5074.5866.9965.6255.1852.82
Earnings Per Share0.390.22-1.62-1.63-1.05-0.81-0.690.080.67-0.15
EPS Growth77.27%-------88.06%--
Operating Cash Flow152101-94.33-106-38.00-47.14-29.61-35.29-0.7049.94
Capital Expenditures-14.74-24.78-6.93-4.10-1.93-1.57-0.51-0.94-0.510.02
Free Cash Flow13776.59-101-110-39.92-48.71-30.11-36.23-1.2049.96
Cash & Equivalents674656520312384199150177133133
Total Debt496388370-------
Net Cash / Debt178268151312384199150177133133
Assets1,306993818365475243155196138144
Liabilities66951244550.2150.3334.3334.2741.6178.29125
Book Value63748137231542420912015460.0819.35
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Neurocrine Biosciences, Inc.
Country United States
Employees 825
CEO Kevin Gorman

Stock Information

Ticker Symbol NBIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NBIX
IPO Date May 23, 1996

Description

Neurocrine Biosciences, a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.